Last reviewed · How we verify
cardiac output changes with "ondansetron"
Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Radiation-induced nausea and vomiting, Post-operative nausea and vomiting (PONV).
At a glance
| Generic name | cardiac output changes with "ondansetron" |
|---|---|
| Also known as | cardiac output: CO (cm3 / min) = ITV * S * HR. ITV (cm) = integral time velocity is measured by pulsed doppler at the level of the ascending aorta, on apical cut. |
| Sponsor | University Tunis El Manar |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ondansetron selectively antagonizes 5-hydroxytryptamine (serotonin) at 5-HT3 receptors located in the chemoreceptor trigger zone and on vagal afferent nerves in the gastrointestinal tract. By blocking these receptors, it prevents the emetic signal cascade triggered by chemotherapy, radiation, or post-operative stimuli. The cardiac output changes noted in this research may relate to vagal tone modulation or direct cardiovascular effects of 5-HT3 antagonism, though ondansetron's primary therapeutic action is antiemetic.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Radiation-induced nausea and vomiting
- Post-operative nausea and vomiting (PONV)
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- QT prolongation
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: